Samchundang Pharm

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 4.61B pre-tax profit sensitivity for 10% USD/EUR/JPY/CAD/GBP exchange rate move, up from KRW 3.16B prior year
• • KRW 118.7B financial liabilities due within 1 year, up from KRW 70.3B prior year

Management Discussion & Analysis

• • Revenue KRW 231.8B (+9.9% YoY); operating profit KRW 846.7M (+220.5% YoY); net income KRW 1.2B (+336.9% YoY)
• • Ophthalmology segment 61.1% of sales; overseas Aillia biosimilar (SCD411) sales in Canada drove profit increase

Business Overview

• • Core business model: prescription pharmaceutical manufacturing and sales, with ophthalmic products comprising 61.06% of sales in FY2025
• • Aflibercept biosimilar (SCD411) reached major regulatory approvals in Japan (Sep 2025), Canada (Jun 2025), and Europe (Aug 2025) with multiple exclusive sales contracts

What are the latest Samchundang Pharm DART filings in 2026?

Samchundang Pharm (KRX code 000250) has filed an annual report on March 20, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Samchundang Pharm file its most recent annual report?

Samchundang Pharm filed its most recent annual report on March 20, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Samchundang Pharm's KRX stock code?

Samchundang Pharm's KRX stock code is 000250. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 000250 to look up all Samchundang Pharm disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Samchundang Pharm file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Samchundang Pharm.

Where can I find Samchundang Pharm financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Samchundang Pharm annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.